People on the Move
DIA China
DIA, a non-profit association for collaboration across the pharmaceutical and biologics industries with more than 18,000 members, has named Haijun (Lou) Dong MD of DIA China.
Dong previously served as CEO for Lilly China R&D, and CEO of Impact Therapeutics, as well as senior roles at Roche and other Chinese and US companies. He is also a professor at Nanjing University of Technology.
He assumes the role upon the retirement of Jane Cai, the current DIA China regional director. Under Cai’s leadership, DIA China was established in 2011 as a separate legal entity, DIA Beijing Healthcare Information Consulting Ltd.
Since then, DIA China has increased its annual educational programmes and membership. Dong has been tasked with accelerate DIA’s presence in China further.
The association works as a forum for pharmaceutical professionals across disciplines to access information, through DIA-organised training and conferences.
Our sister site’s coverage of last month’s DIA Euromeeting can be found here.
